A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood

Hemophilia A Clinical Trial

— Alfa-PROTECT  

Official title:

A Phase 3, Single Group Treatment, Open-label, Study to Evaluate the Safety of BAY 94-9027 Infusions for Prophylaxis and Treatment of Bleeding in Previously Treated Children Aged 7 to <12 Years With Severe Hemophilia A

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05147662
• Other study ID #: 21824
• Secondary ID: 2021-004858-30
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: March 23, 2022
• Est. completion date: July 10, 2025

Study information

• Verified date: June 2024
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Researchers are looking for a better way to treat hemophilia A. Hemophilia A is a genetic disorder where the body does not create enough of a protein called clotting factor 8 (FVIII) present in the blood. People with hemophilia A may bleed for a long time from minor wounds, have painful bleeding into joints, or have internal bleeding. In severe hemophilia A (clotting factor 8 levels less than 1%) bleedings are more likely to happen.

In this study researchers want to learn more about the treatment called BAY94-9027. BAY94-9027 is an injectable medicine used to replace missing clotting factor 8. In BAY94-9027 the clotting factor 8 has been pegylated (combined with a substance called polyethylene glycol (PEG)). This is to make the treatment last longer in the body so that less injections are required. BAY94-9027 is already available for the prevention and treatment of bleeding in adults and children who are 12 years and older. BAY 94-9027 is also called Jivi.

BAY94-9027 is not yet available for children aged 7 to less than 12 years. One potential specific risk of pegylated drugs is that proteins in the blood called antibodies are built. These may attach to the pegylation part of the drug and this in turn may lead to allergic reactions and the drug not working as well as it should during first 4 infusions. In studies that have been done so far, this has been seen in some children younger than six years, but not in 29 children aged 6 to less than 12 years treated with BAY94-9027. Further safety information related to how the body reacts to BAY94-9027 is however still needed for this age group.

The main purpose of this study is to learn how safe BAY94-9027 is (safety) and how it affects the body (tolerability) in previously treated children with severe hemophilia A who are between 7 to less than 12 years. To answer this question, the researchers will study information about two medical problems of special interest, if allergic reactions occur (also called hypersensitivity) and if the drug is not working as well as it should (also called loss of efficacy) during the first 4 infusions.

Allergic reactions may range from mild local reactions to widespread effects such as shortness of breath, skin rashes and low blood pressure. Only allergic reactions related to the study treatment will be considered.

The assessment if loss of efficacy occurred will be based on the occurrence of bleeding, the clotting factor 8 level in blood after injection called recovery, clotting factor 8 inhibitor tests and measurement of antibodies against the PEG.

The study has two parts, A and B. Part A takes 6 months and part B takes 18 months. In part A the participants will receive two injections of BAY94-9027 per week. In part B, the number of injections may be decreased, with up to five days between the injections. The participants in this study will visit the study site around 14 times and will have 15 phone visits. In part A, visit 1 is for screening. Visits 2 to 5 take place twice a week for two weeks. Visit 6 two weeks after visit 5, visits 7 to 10 take place monthly with visit 11 six weeks after visit

10. In part B, site visits will occur on month 9, 12, 18 and 24 and phone calls every month between the site visits. The participants' and their caregivers will record in an electronic patient diary information about when the study treatment was given and bleeding episodes that have happened.

During the study, the study doctors and their team will

• take blood samples,

• do physical examinations,

• review the participants' electronic diary

• ask questions about the participants' quality of life,

• ask the participants questions about how they are feeling and what adverse events they are having An adverse event is a medical problem that happens during the study. Doctors keep track of all adverse events that happen in study, even if they do not think the adverse events might be related to the study treatments.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 33
• Est. completion date: July 10, 2025
• Est. primary completion date: January 4, 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 7 Years to 11 Years

Eligibility

Inclusion Criteria:

• Participants with severe hemophilia A (participant's own FVIII activity [FVIII:C] <1%)

• Participants must be previously treated with FVIII concentrate(s) (plasma derived or recombinant) for a minimum of 50 exposure days (EDs) at the time of signing the informed consent

• Participant has understood the study if appropriate for his age, informed consent must be signed by the parent, the participant can only sign the assent

• Willingness and ability of participants and/or parents /caregivers to complete training in the use of the electronic patient diary (EPD) and to document infusions during the study

Exclusion Criteria:

• History of FVIII inhibitors

• Current evidence of inhibitor to FVIII measured using the Nijmegen-modified Bethesda assay (>0.6 BU/mL) at the time of screening (central laboratory)

• Any other inherited or acquired bleeding disorder in addition to hemophilia A (e.g. von Willebrand disease, hemophilia B)

• Known hypersensitivity or allergic reaction to drug substance, excipients or mouse or hamster protein

• Any other significant medical condition that the investigator feels would be a risk to the patient or would impede the study

• Requires any pre-medication to tolerate FVIII treatment (e.g. antihistamines)

• Planned major surgery during the study

• Any individual who is receiving chemotherapy, immune modulatory drugs other than anti-retroviral chemotherapy, or chronic use of oral or intravenous (IV) corticosteroids (> 14 days) within the last 3 months

• Any individual who received commercially available subcutaneous factor substitution therapy (emicizumab) within the last 6 months

• The participant is currently participating in another investigational drug study or has participated in a clinical study involving an investigational drug within 30 days of study entry or previous participation in a clinical study with BAY94-9027

Related Conditions & MeSH terms

• Children
• Hemophilia A
• Hemorrhage

Intervention

Biological:
• Damoctocog alfa pegol (Jivi, BAY94-9027)
Part A: 40 IU/kg (up to 60 IU/kg at the investigator's discretion), two times per week (2x/week) with the first 4 infusions under medical supervision. Thereafter, participants will continue their treatment as home treatment. Dose may be increased up to 60 IU/kg if needed at any time during the study at the investigator's discretion. Part B: Each participant may continue on prophylaxis dose regimen as prescribed in part A (40 - 60 IU/kg, 2x per week) or adjustments to prophylaxis dose / dose frequency can be made at the investigator's discretion (based on the bleeding events and individual needs): Dose frequency may be decreased to every 5 days with a prophylaxis dose of 60 IU/kg.

Locations

Country	Name	City	State
Argentina	Instituo Hematología Arbesú	Godoy Cruz	Mendoza
Argentina	Hospital de Niños Sor María Ludovica	La Plata	Buenos Aires
Argentina	Instituto de Hematología Dr. Rubén Dávoli	Rosario	Santa Fe
Brazil	Hospital das Clínicas de Campinas - UNICAMP	Campinas	Sao Paulo
Brazil	Many Locations	Multiple Locations
Brazil	Hosp Clínicas Facult. Med. de Ribeirão Preto / USP	Ribeirão Preto	Sao Paulo
Brazil	HEMORIO	Rio de Janeiro
Brazil	Irmandadade da Santa Casa de Misericordia de Sao Paulo (iSANTACASA)	São Paulo	Sao Paulo
Canada	McMaster Children's Hospital	Hamilton	Ontario
Canada	Many Locations	Multiple Locations
Italy	IRCCS Ospedale Pediatrico Bambino Gesù	Roma	Lazio
Norway	OUS Rikshospitalet Klinisk Forskningspost Barn	Oslo
Turkey	Acibadem Adana Hastanesi	Adana
Turkey	Hacettepe Universitesi Tip Fakultesi	Ankara
Turkey	Akdeniz Universitesi Tip Fakultesi Hastanesi	Antalya
Turkey	Gaziantep Universitesi Tip Fakultesi	Gaziantep
Turkey	Ege Universitesi Tip Fakultesi	Izmir
Turkey	Many Locations	Multiple Locations
Turkey	Ondokuz Mayis Uni Tip Fakultesi	Samsun
United States	Arnold Palmer Hospital for Children	Orlando	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Countries where clinical trial is conducted

United States,  Argentina,  Brazil,  Canada,  Italy,  Norway,  Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AESI (hypersensitivity and loss of efficacy) associated with the first 4 exposure days leading to discontinuation	AESI = adverse events of special interest	Up to 6 months
Secondary	Adverse drug reactions (ADRs)		Up to 6 months
Secondary	Anti-drug antibody (ADA) development		Pre-infusion and up to 6 months
Secondary	The number of participants with confirmed Factor VIII inhibitors		Pre-infusion and up to 6 months
Secondary	Annualized bleeding rate (ABR)		Up to 24 months
Secondary	BAY94-9027 consumption		Up to 24 months
Secondary	Number of infusions/month and year (Annualized Infusion Rate)		Up to 24 months

External Links

•   Click here to find information for studies related to Bayer products. To find this study enter the ClinicalTrials.gov identifier (NCT) number or Bayer Study Identifier (ID) in the search field.